About Sofregen
Sofregen is a Healthcare company based in Medford (United States) founded in 2014 by Anh Hoang. Silk-derived biomaterials are developed for soft tissue repair in surgery. Sofregen has raised $17.8 million across 2 funding rounds from investors including Anzu Partners and Polaris Partners. The company has 8 employees. Sofregen has completed 1 acquisition, including SERI Surgical Scaffold. Its chief executive, as recorded, is Jenna Abelli. Sofregen offers products and services including Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its legal entity is SOFREGEN MEDICAL INC. Its competitors include Revance Therapeutics, Castle Creek Pharma and Organogenesis; 3 of its 3 listed competitors have raised funding.
Company details
Sofregen is developing the use of silk in a variety of forms to help physicians address soft tissue defects. The technology was developed at Tufts University and the University of Pittsburgh. As part of their growing portfolio of medical technologies, they have recently become the new supplier of SERI Surgical Scaffold, the only silk-based biological mesh. Unlike other products that are derived from human cadaver or animal tissue, SERI Surgical Scaffold is an ultra-pure, sterile, silk-derived bioprotein that is claimed to be delivering consistent and predictable characteristics and facilitating native tissue generation over time.
- Headquarters Medford, United States
- Employees 8
- Founders Anh Hoang
- SectorsHealthcare
- Email••••••••
- Website sofregen.com
- Social LinkedIn X Facebook
- Legal Name Sofregen Medical Inc.
- Total Equity Funding$17.8M (USD)
in 2 rounds
- Latest Funding Round$8.1M (USD), Series B
Sep 2019
- InvestorsAnzu Partners
& 1 more
- Employee Count8
- Investments & Acquisitions
Products & Services of Sofregen
Sofregen offers a comprehensive portfolio of products and services, including Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform.
Injectable biomaterial for vocal fold medialization and regeneration procedures.
Biomaterial scaffold for soft tissue support in surgical applications.
Platform for developing silk-based products for tissue regeneration.
Funding Insights of Sofregen
Sofregen has successfully raised a total of $17.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $8.1 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.8M
- Total Rounds 2
- Last Round Series B — $8.1M
- First Round $9.7M
(Sep 2017)
- Investors Count 2
All 2 funding rounds of Sofregen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $8.1M | Series B | – | Anzu Partners | – |
| Sep 2017 | $9.7M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Sofregen
Sofregen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Anzu Partners and Polaris Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in industrial and life sciences technology companies. | anzupartners.com | Washington, Dc, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States |
Investor details for Sofregen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sofregen
3 people are tracked at Sofregen (2 in leadership, 1 in board & advisors); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Anh Hoang | Co-Founder & CSO | Leadership |
Jenna Abelli | CEO & President | Leadership |
Jonathan Hartmann | Director | Board & advisors |
Complete people profiles for Sofregen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sofregen
Sofregen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SERI Surgical Scaffold.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Standalone plastic surgery hospital services are provided in Medford. | seri.com | Medford, United States | 1996 | Nov 2016 | •••• |
Complete acquisition details for Sofregen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Sofregen
4 dated milestones of Sofregen across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Sofregen is founded.
- Acquisition Acquires SERI Surgical Scaffold.
- Funding First funding round of $9.7M.
- Funding Latest funding round, Series B, of $8.1M.
Competitors of Sofregen
Sofregen has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Castle Creek Pharma and Organogenesis.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| organogenesis.com | 1985 | Canton, United States | $30M | 856 | Regenerative therapies for wound care are developed and commercialized. |
Detailed competitors of Sofregen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Sofregen (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sofregen
Complete news archive for Sofregen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sofregen
Sofregen was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Sofregen is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Jenna Abelli is the CEO of Sofregen, as recorded in our data.
Sofregen is a funded company, having raised a total of $17.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $9.7M, raised on Sep 2017.
Sofregen has 8 employees.
Sofregen is developing the use of silk in a variety of forms to help physicians address soft tissue defects. The technology was developed at Tufts University and the University of Pittsburgh. As part of their growing portfolio of medical technologies, they have recently become the new supplier of SERI Surgical Scaffold, the only silk-based biological mesh. Unlike other products that are derived from human cadaver or animal tissue, SERI Surgical Scaffold is an ultra-pure, sterile, silk-derived bioprotein that is claimed to be delivering consistent and predictable characteristics and facilitating native tissue generation over time.
Sofregen's top competitors include Revance Therapeutics, Organogenesis and Castle Creek Pharma.
Sofregen offers Silk Voice Injectable Implant, SERI Surgical Scaffold, and Silk Protein Platform.
Sofregen has made 1 acquisition, including SERI Surgical Scaffold.
Sofregen has 2 investors. Key investors include Anzu Partners, and Polaris Partners.
Sofregen operates through Sofregen Medical Inc..